Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613885 | 0.79 | CYP2D6 (0.38) | CYP2D6CYP2C19 | |
| Oxalic Acid SCHEMBL8080680 | 0.76 | CYP2D6 (0.35) | CYP2D6CYP2C19 | |
| SCHEMBL32689218 | 0.76 | CYP2D6 (0.41) | CYP2D6CYP2C19 | |
| SCHEMBL5837479 | 0.74 | CYP2D6 (0.35) | TSHRALDH1A1TDP1CYP2D6CYP2C19 | |
| SCHEMBL7638350 | 0.74 | CYP2D6 (0.39) | CYP2D6CYP2C19 | |
| SCHEMBL5837266 | 0.73 | CYP2D6 (0.34) | CYP2D6CYP2C19 | |
| SCHEMBL350877 | 0.73 | CYP2D6 (0.46) | CYP2D6CYP2C19 | |
| SCHEMBL32688908 | 0.72 | CYP2D6 (0.38) | CYP2D6CYP2C19 | |
| SCHEMBL296007 | 0.72 | CYP2D6 (0.31) | CYP2D6CYP2C19 | |
| SCHEMBL5837608 | 0.71 | TSHR (0.37) | TSHRCA2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416591-A1 | DUAL CURE SYSTEM FOR THE CHEMICAL FASTENING OF AN ANCHORING MEANS IN A BOREHOLE | HILTI AKTIENGESELLSCHAFT (LI) | 2023-12-28 | — | — | US | disclosed |
| EP-4244271-A1 | DUAL CURE SYSTEM FOR CHEMICALLY FASTENING ANCHORING MEANS IN A DRILL HOLE | Hilti Aktiengesellschaft (LI) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022101025-A1 | DUAL CURE SYSTEM FOR CHEMICALLY FASTENING ANCHORING MEANS IN A DRILL HOLE | HILTI AKTIENGESELLSCHAFT (LI) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416591-A1 | DUAL CURE SYSTEM FOR THE CHEMICAL FASTENING OF AN ANCHORING MEANS IN A BOREHOLE | DUOX2, COASY, OSBP | THRB 2035/4885TSHR 3353/4885ALDH1A1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.